Call for candidates Funding for services from Biological Resource Centers and/or Platforms

Funding for services to validate projects involving biomarkers, therapeutic molecules, and technology approaches having received, or in the process of receiving, the MUSE label.

Objective

Provide funding for obtaining services from Biological Resource Centers and/or Platforms available within the MUSE I-SITE scope. Services should help validate emerging projects involving biomarkers, therapeutic molecules, and technology approaches. These projects may have already received the MUSE KIM label, or in the process.

Context

The MUSE Key Initiative “Biomarkers & Therapy” (KIM B&T, scientific management: Sylvain Lehmann; operational management: Brigitte Couette) is a proactive and transversal action led by MUSE I-SITE, set up to favor synergy for Research – Education – Society, with the goal of promoting translational research in the fields of biomarkers, diagnostics, and targeted therapies, and to assist strong, innovative, and high-value projects.

This key initiative’s mission is to:

  • stimulate the ecosystem and bring about unifying actions
  • Participate in educating students by offering grants at the Master’s level and a year of research for interns
  • Help set up mechanisms for collecting and standardizing patient data and linking it to data in biobanks.
  • Share its expertise to support project progression along the path to technological maturity, enabling projects to then benefit from regional promotion programs.

KIM B&T has launched a call for candidates entitled “Labeling Emerging Projects for Biomarkers and Targeted Therapy” in the context of personalized medicine. The purpose of this call for candidates is not to fund the projects themselves, but rather to facilitate the emergence of new projects and new directions by awarding the MUSE label, recognized by promotional valorization organizations including SATT AxLR and the Occitanie Region. The MUSE label enables project leaders to benefit from assistance leading to project valorization, along with facilitated access to technological and clinical platforms and regional biobanks.

This “Funding for services from Biological Resource Centers and/or Platforms” call for candidates is intended to provide support for the “Labeling of Emerging Biomarkers and Targeted Therapy” call for candidates by offering financial support of 5,000 € to 10,000 € enabling project leaders to fund services and obtain biological samples. A total amount of 70,000 € is dedicated to this action.

Application conditions

To respond to this call for candidates, please complete the form “Fiche_demande_Prestations_Plateformes_CRB” attached to this document and send it by e-mail to “Request for services”.

The date limit for submitting your candidacy is February 29, 2020 (see calendar below). Members of the MUSE Assistance Committee will evaluate your request with absolute confidentiality and get back to you as quickly as possible.

Eligibility

To be eligible, requests must be submitted by a project leader who’s project has already obtained the MUSE KIM label, or who’s label is in progress; or by a person submitting their candidacy for this call for candidates jointly with candidacy for the “Labeling Emerging Projects for Biomarkers and Targeted Therapy” call for candidates.

To be eligible, services must be provided within the scope of the MUSE I-SITE to the greatest extent possible. Otherwise, a valid reason must be provided.

  • The platforms that may be used are those offered by UMS BioCampus Montpellier and UMS CEMIPAI, as well as clinical and technological platforms open to outside users (that is, not overloaded by the hosting laboratory’s own needs). Those platforms must offer a pricing structure and, if possible, be certified ISO 9001 or equivalent according to the type of activity (ISO/NFS).
  • For biological resources, the project leader will leverage resources found within the scope of BBLRO (CRB Nîmes, CRB Montpellier, and CRB ICM).

Evaluating and selecting projects

The KIM committee will classify the projects selected to receive funding in priority order based on the following criteria:

  • Impact of the service request on the emerging project’s progression as well as its capacity to generate future value in relation to a clinical or technological need in the field of diagnostics or targeted therapy.
  • Lack of other funding options

There are two possible scenarios:

A) The request is submitted by a project leader who wants to obtain services to validate biomarkers, therapeutic molecules, and/or technology approaches as part of their project that is already labeled or assisted by the MUSE KIM

Funding is available immediately if the project is selected by the KIM Committee.

B) The request is submitted by a candidate whose project is not yet labeled or assisted by the MUSE KIM

The candidate must respond to both calls for candidates: “Funding for services from Biological Resource Centers and/or Platforms” and “Labeling Emerging Projects for Biomarkers and Targeted Therapy”.

If the project is selected by the KIM Committee, funding is only made available following an interview with the project leader by the KIM Labeling Committee (Wednesday, March 11, 2020).

Results

Decisions will be formalized by e-mail sent to you as quickly as possible.

https://muse.edu.umontpellier.fr/files/2018/10/ligne.png

“BIOMARKERS & THERAPY” KIM SUPPORT COMMITTEE

The committee’s role is to:

  • Preselect candidate projects for the MUSE label and interview project leaders
  • Share expertise to support projects in their progression towards a level of maturity that enables them to benefit from regional promotion programs
  • Certify projects with the MUSE KIM label

The committee is made up of experts from the biomarker, diagnostics, and therapy sector covering research, clinical aspects, platforms, promotion, industry, and institutions. They represent the entire value chain for diagnostic biomarkers and targeted therapy.

  • Jean-Pierre Bleuse (Montpellier Regional Cancer Institute)
  • Joël Bockaert (Institute of Functional Genomics)
  • Armelle Bonet-Kerrache (Inserm)
  • Édouard Bosvert (BB-LRO)
  • Jean-Paul Brouillet (Nîmes CHU)
  • Karine Chorro (PHOST’IN)
  • Virginie Coste (Business Developer, MUSE)
  • Brigitte Couette (KIM B&T)
  • Nathalie Coux (Montpellier CHU Platforms)
  • John De Vos (Montpellier CHU)
  • Jeannette Fareh (Bio-Rad)
  • Bénédicte Fauvel (SATT AxLR)
  • Chantal Fournier (French Blood Bank)
  • Laurent Garnier (Eurobiomed/Euromediag)
  • Valérie Gibert (Nîmes CHU)
  • Bénédicte Jardin-Watelet (Thermo Fisher Scientific)
  • Laurent Journot (UMS BioCampus Montpellier)
  • Géraldine Karbouch (SATT AxLR)
  • Gaëtan Lan Sun Luk (University of Montpellier)
  • Daniel Laune (KYomed INNOV)
  • Emmanuel Le Bouder (Eurobiomed)
  • Sylvain Lehmann (KIM B&T)
  • Gaspard Lépine (MUSE)
  • Sophie Marchal (Occitanie Region)
  • Gérard Mathis (formerly of Cisbio)
  • Franck Molina (Sys2diag)
  • Marjorie Monleau (AD’OCC Regional Agency)
  • André Pelegrin (Montpellier Oncology Research Institute)
  • Guillaume Rochet (CNRS)
  • Philippe Rondard (Functional Genomics Institute)
  • Gilles Subra (Balard Chemistry Cluster)
  • Jamal Tazi (Molecular Genetics Institute of Montpellier)
  • Anne Verchere (Montpellier CHU)